| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 0 | 110 | 0 | 80 | -280 |
| Sales Growth | -100.00% | unch | -100.00% | +128.57% | unch |
| Net Income | -200 | -180 | -430 | -300 | -810 |
| Net Income Growth | -11.11% | +58.14% | -43.33% | +62.96% | -24.62% |
Arch Biopartners Inc Ord (ACHFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Arch Biopartners Inc. is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation. Arch Biopartners Inc. is based in TORONTO.
Fiscal Year End Date: 09/30